NCT00171912 2017-02-23
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Novartis
Phase 2 Completed
Clinical Trials
11 trialsNCT00052494 2015-07-23
Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
University Health Network, Toronto
Phase 1 Completed
NCT01011075 2015-07-03
6137p
New Mexico Cancer Research Alliance
Phase 2 Completed
NCT02127372 2014-09-15
Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571
Duke University
Phase 1/2 Terminated
NCT00323362 2014-05-22
Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00425646 2013-05-06
Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
University of Washington
Phase 2 Completed
NCT00248482 2013-04-29
Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00222144 2012-08-07
Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer
University of Kansas Medical Center
Phase 2 Completed
NCT01083589 2012-01-11
Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00193349 2010-06-28
Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00045604 2008-07-24
Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed